WO1999066054A3 - Erythropoietin analog-human serum albumin fusion protein - Google Patents

Erythropoietin analog-human serum albumin fusion protein Download PDF

Info

Publication number
WO1999066054A3
WO1999066054A3 PCT/US1999/013438 US9913438W WO9966054A3 WO 1999066054 A3 WO1999066054 A3 WO 1999066054A3 US 9913438 W US9913438 W US 9913438W WO 9966054 A3 WO9966054 A3 WO 9966054A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
serum albumin
human serum
albumin fusion
erythropoietin analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/013438
Other languages
French (fr)
Other versions
WO1999066054A2 (en
Inventor
Michael W Young
Harry M Meade
Ian M Krane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
rEVO Biologics Inc
Original Assignee
Genzyme Transgenics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Transgenics Corp filed Critical Genzyme Transgenics Corp
Priority to HK01105360.0A priority Critical patent/HK1036475B/en
Priority to DE69933216T priority patent/DE69933216T2/en
Priority to EP99928656A priority patent/EP1088084B1/en
Priority to AU45668/99A priority patent/AU775422B2/en
Priority to CA002330527A priority patent/CA2330527A1/en
Priority to DK99928656T priority patent/DK1088084T3/en
Priority to JP2000554863A priority patent/JP4087563B2/en
Publication of WO1999066054A2 publication Critical patent/WO1999066054A2/en
Publication of WO1999066054A3 publication Critical patent/WO1999066054A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Erythropoietin analog-human serum albumin (EPOa-hSA) fusion protein and methods of making and using the fusion protein.
PCT/US1999/013438 1998-06-15 1999-06-15 Erythropoietin analog-human serum albumin fusion protein Ceased WO1999066054A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
HK01105360.0A HK1036475B (en) 1998-06-15 1999-06-15 Erythropoietin analog-human serum albumin fusion protein
DE69933216T DE69933216T2 (en) 1998-06-15 1999-06-15 ERYTHROPOIETIN ANALOG HUMAN SERUM ALBUMIN FUSION PROTEIN
EP99928656A EP1088084B1 (en) 1998-06-15 1999-06-15 Erythropoietin analog-human serum albumin fusion protein
AU45668/99A AU775422B2 (en) 1998-06-15 1999-06-15 Erythropoietin analog-human serum albumin fusion
CA002330527A CA2330527A1 (en) 1998-06-15 1999-06-15 Erythropoietin analog-human serum albumin fusion
DK99928656T DK1088084T3 (en) 1998-06-15 1999-06-15 Erythropoietin analog-human serum albumin fusion protein
JP2000554863A JP4087563B2 (en) 1998-06-15 1999-06-15 Erythropoietin analog-human serum albumin fusion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8934398P 1998-06-15 1998-06-15
US60/089,343 1998-06-15

Publications (2)

Publication Number Publication Date
WO1999066054A2 WO1999066054A2 (en) 1999-12-23
WO1999066054A3 true WO1999066054A3 (en) 2000-04-06

Family

ID=22217149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013438 Ceased WO1999066054A2 (en) 1998-06-15 1999-06-15 Erythropoietin analog-human serum albumin fusion protein

Country Status (10)

Country Link
US (4) US6548653B1 (en)
EP (1) EP1088084B1 (en)
JP (1) JP4087563B2 (en)
AT (1) ATE339507T1 (en)
AU (1) AU775422B2 (en)
CA (1) CA2330527A1 (en)
DE (1) DE69933216T2 (en)
DK (1) DK1088084T3 (en)
ES (1) ES2273497T3 (en)
WO (1) WO1999066054A2 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838260B2 (en) 1997-12-08 2005-01-04 Emd Lexigen Research Center Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US6905688B2 (en) 2000-04-12 2005-06-14 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US6969517B2 (en) 2001-05-03 2005-11-29 Emd Lexigen Research Center Corp. Recombinant tumor specific antibody and use thereof
US6972322B2 (en) 1992-01-31 2005-12-06 Aventis Behring L.L.C. Interferon and albumin fusion protein
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7045318B2 (en) 1995-12-30 2006-05-16 Delta Biotechnology Limited Recombinant fusion proteins to growth hormone and serum albumin
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7091321B2 (en) 2000-02-11 2006-08-15 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US7141547B2 (en) 2001-12-21 2006-11-28 Human Genome Sciences, Inc. Albumin fusion proteins comprising GLP-1 polypeptides
US7141651B2 (en) 1999-08-09 2006-11-28 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
US7148321B2 (en) 2001-03-07 2006-12-12 Emd Lexigen Research Center Corp. Expression technology for proteins containing a hybrid isotype antibody moiety
US7169904B2 (en) 2002-12-17 2007-01-30 Emd Lexigen Research Center Corp. Immunocytokine sequences and uses thereof
US7186804B2 (en) 2001-12-04 2007-03-06 Emd Lexigen Research Center Corp. IL-2 fusion proteins with modulated selectivity
US7211253B1 (en) 1999-11-12 2007-05-01 Merck Patentgesellschaft Mit Beschrankter Haftung Erythropoietin forms with improved properties
US7465447B2 (en) 2003-12-31 2008-12-16 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7517526B2 (en) 2000-06-29 2009-04-14 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US7521424B2 (en) 2003-01-22 2009-04-21 Human Genome Sciences, Inc. Albumin fusion proteins
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129390B2 (en) * 1997-10-16 2006-10-31 Avigenics, Inc Poultry Derived Glycosylated Interferon Alpha 2b
US20050181482A1 (en) * 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
DE69933216T2 (en) * 1998-06-15 2007-09-20 GTC Biotherapeutics, Inc., Framingham ERYTHROPOIETIN ANALOG HUMAN SERUM ALBUMIN FUSION PROTEIN
US20030005468A1 (en) * 1998-06-19 2003-01-02 Meade Harry M. Methods and vectors for improving nucleic acid expression
GB9817084D0 (en) * 1998-08-06 1998-10-07 Wood Christopher B A method for promoting extra-heptic production of proteins for the correction of hypoalbuminaemia,anaemia,thrombocytopenia and/or coagulation disorders
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
KR20020039346A (en) * 1999-09-17 2002-05-25 추후보정 Subunit optimized fusion proteins
US20040226053A1 (en) * 2000-10-13 2004-11-11 Meade Harry M. Methods of producing a target molecule in a transgenic animal and purification of the target molecule
ES2311560T3 (en) * 2000-12-07 2009-02-16 Eli Lilly And Company GLP-1 FUSION PROTEINS.
NZ548578A (en) 2001-02-02 2008-03-28 Ortho Mcneil Pharm Inc Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
WO2003030821A2 (en) * 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US7232797B2 (en) 2001-11-28 2007-06-19 Ortho-Mcneil Pharmaceutical, Inc. Erythropoietin dosing regimen for treating anemia
KR100467750B1 (en) * 2001-11-29 2005-01-24 씨제이 주식회사 Fusion protein having the enhanced in vivo activity of erythropoietin
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
WO2003078959A2 (en) 2002-03-11 2003-09-25 Ortho Mcneil Pharmaceutical, Inc Methods for shp1 mediated neuroprotection
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7803362B2 (en) * 2003-01-24 2010-09-28 Synageva Biopharma Corp. Glycosylated interferon alpha
US20040198663A1 (en) * 2003-04-04 2004-10-07 Baker John E. Method of treating cardiac ischemia by using erythropoietin
US20050079546A1 (en) * 2003-05-01 2005-04-14 Dasa Lipovsek Serum albumin scaffold-based proteins and uses thereof
JP5010923B2 (en) * 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Albumin fusion protein
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
EP1796731A2 (en) * 2004-09-03 2007-06-20 Alza Corporation Endogenously-formed conjugate of albumin
EP1976876A4 (en) * 2005-12-22 2010-01-13 Conjuchem Biotechnologies Inc Process for the production of preformed conjugates of albumin and a therapeutic agent
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US7812127B2 (en) 2006-03-17 2010-10-12 Synageva Biopharma Corp. Glycosylated human G-CSF
DE602007007923D1 (en) * 2006-04-11 2010-09-02 Csl Behring Gmbh METHOD FOR INCREASING THE IN VIVO RECOVERY OF THERAPEUTIC POLYPEPTIDES
CN101062407A (en) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 Function of erythropoietin in the preventing and treating of retinal injury
AU2007258609B2 (en) 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
WO2008030558A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US20090105462A1 (en) * 2006-11-09 2009-04-23 Ivarie Robert D Glycosylated erythropoietin
EP2076530A4 (en) * 2006-11-09 2010-04-07 Synageva Biopharma Corp ERYTHROPOIETINE DERIVED FROM BIRDS
WO2008056961A1 (en) * 2006-11-10 2008-05-15 Boryung Pharmaceutical Co., Ltd A novel fusion protein, cell lines expressing the same and preparation method thereof
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
CA2673459C (en) * 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
AR065083A1 (en) 2007-02-02 2009-05-13 Amgen Inc HEPCIDINE, HEPCIDINE ANTAGONISTS AND METHODS OF USE
CA2720628A1 (en) 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
CN101855352A (en) * 2007-08-08 2010-10-06 Cho-A制药株式会社 Mammary gland-specific human erythropoietin expression vector, transgenic animal and method for producing human erythropoietin by using same
AU2008304111B2 (en) * 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
CN101932231A (en) * 2008-01-07 2010-12-29 辛那杰瓦生物制药股份有限公司 Glycosylation in poultry
AU2009206306B2 (en) 2008-01-25 2013-06-06 Amgen Inc. Ferroportin antibodies and methods of use
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
JP2011519279A (en) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド Anti-hepcidin antibodies and methods of use
WO2010002082A1 (en) * 2008-06-30 2010-01-07 Cho-A Pharm Co., Ltd. A gene of porcine beta-casein, a promoter of the same and the use thereof
CN102124109B (en) * 2008-06-30 2013-10-16 Cho-A制药有限公司 Gene of porcine alpha-S1 casein, a promoter of the same and use thereof
PL2342223T3 (en) 2008-09-26 2017-09-29 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
EP2349332B1 (en) 2008-11-13 2019-10-23 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation bmp-6
US8815242B2 (en) * 2009-05-27 2014-08-26 Synageva Biopharma Corp. Avian derived antibodies
MX344382B (en) 2009-10-23 2016-12-14 Amgen Inc * Vial adapter and system.
JP5737597B2 (en) 2009-11-19 2015-06-17 浙江大学 Non-natural collagen-like protein and its application
ES2545411T5 (en) 2010-06-07 2024-04-05 Amgen Inc drug delivery device
US9074015B2 (en) 2010-07-28 2015-07-07 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
SG191781A1 (en) 2010-12-30 2013-08-30 Lab Francais Du Fractionnement Glycols as pathogen inactivating agents
CA2831100C (en) 2011-03-31 2020-02-18 Mark Dominis Holt Vial adapter and system
CA3021845C (en) 2011-04-20 2022-03-29 Amgen Inc. Autoinjector apparatus
AR087433A1 (en) * 2011-08-08 2014-03-26 Merck Sharp & Dohme N-GLICOSILATED INSULIN ANALOGS
LT3045187T (en) 2011-10-14 2019-07-10 Amgen Inc. Injector and method of assembly
SI3081249T1 (en) 2012-11-21 2021-03-31 Amgen Inc. Drug delivery device
AU2014217561B2 (en) 2013-02-13 2018-11-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-TNF-alpha antibodies and uses thereof
BR112015019348A2 (en) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement METHODS FOR PRODUCING GLYCOSYLATION MODIFIED AND SIALYLATION ENHANCED PROTEIN, TO ENHANCE SIALYL TRANSFERASE ACTIVITY IN THE MAMMARY GLAND AND TO PRODUCE SIALYL TRANSFERASE, GLYCOSYLATION MODIFIED PROTEIN OR SIALYLATION ENHANCED PROTEIN, COMPOSITION, SIALYL TRANSFERASE, MAMMALIAN, AND TRANSGENE MAMMARY EPITHELIAL
MY199344A (en) 2013-02-18 2023-10-24 Vegenics Pty Ltd Ligand binding molecules and uses thereof
CN105142695B (en) 2013-03-15 2020-06-02 安进公司 Body contour adaptable autoinjector device
EP2968775B1 (en) 2013-03-15 2019-12-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
TWI580451B (en) 2013-03-15 2017-05-01 安美基公司 Cassette for an injector and method of using an autoinjector apparatus having an autoinjector and a cassette
SG11201507878SA (en) 2013-03-22 2015-10-29 Amgen Inc Injector and method of assembly
US10611826B2 (en) 2013-07-05 2020-04-07 Laboratoire Français Du Fractionnement Et Des Biotechnologies Affinity chromatography matrix
EP3060281B1 (en) 2013-10-24 2019-01-30 Amgen Inc. Drug delivery system with temperature-sensitive control
EP3421066B1 (en) 2013-10-24 2021-03-03 Amgen Inc. Injector and method of assembly
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
JP6640113B2 (en) 2014-05-07 2020-02-05 アムジエン・インコーポレーテツド Auto-injector with impact reducing element
CN112237662B (en) 2014-06-03 2022-10-21 安姆根有限公司 Drug delivery system and method of use
WO2016061220A2 (en) 2014-10-14 2016-04-21 Amgen Inc. Drug injection device with visual and audio indicators
EP3848072A1 (en) 2014-12-19 2021-07-14 Amgen Inc. Drug delivery device with proximity sensor
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
WO2016138434A1 (en) 2015-02-27 2016-09-01 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
FR3038517B1 (en) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
EP3365363A1 (en) 2015-10-23 2018-08-29 Apogenix AG Single-chain gitr-receptor agonist proteins
ES2755717T3 (en) 2015-12-09 2020-04-23 Amgen Inc Autoinjector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
US11200298B2 (en) 2016-03-15 2021-12-14 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
EP3455142B1 (en) 2016-05-13 2023-08-09 Amgen Inc. Vial sleeve assembly
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
US11752258B2 (en) 2017-02-17 2023-09-12 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
US11369736B2 (en) 2017-02-17 2022-06-28 Amgen Inc. Cannula insertion and retraction mechanisms
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
KR102627069B1 (en) 2017-03-07 2024-01-18 암겐 인코포레이티드 Needle insertion due to overpressure
EP3592404A1 (en) 2017-03-09 2020-01-15 Amgen Inc. Insertion mechanism for drug delivery device
EP3570871B1 (en) 2017-03-20 2020-11-18 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
KR102651078B1 (en) 2017-03-28 2024-03-22 암겐 인코포레이티드 Plunger rod and syringe assembly system and method
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
JP7200134B2 (en) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド Torque driven drug delivery device
JP7195276B2 (en) 2017-06-22 2022-12-23 アムジエン・インコーポレーテツド Collision/shock reduction due to device activation
MA49461A (en) 2017-06-23 2020-04-29 Amgen Inc ELECTRONIC DRUG DELIVERY DEVICE INCLUDING A CAP ACTIVATED BY A SWITCH ASSEMBLY
MA49562A (en) 2017-07-14 2020-05-20 Amgen Inc NEEDLE INSERTION-RETRACTION SYSTEM FEATURING A DOUBLE-TORSION SPRING SYSTEM
EP3655063A1 (en) 2017-07-21 2020-05-27 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
MA49677A (en) 2017-07-25 2021-04-21 Amgen Inc DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSOCIATED ASSEMBLY PROCESS
MA49838A (en) 2017-08-09 2020-06-17 Amgen Inc DRUG DELIVERY SYSTEM WITH CHAMBER HYDRAULIC-PNEUMATIC PRESSURE
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. Flow adapter for drug delivery device
CN111132711B (en) 2017-10-06 2022-07-01 安进公司 Drug delivery device with interlocking components and related assembly methods
MA50348A (en) 2017-10-09 2020-08-19 Amgen Inc DRUG ADMINISTRATION DEVICE INCLUDING A TRAINING ASSEMBLY AND ASSOCIATED ASSEMBLY PROCEDURE
WO2019090086A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
IL273664B1 (en) 2017-11-06 2026-02-01 Amgen Inc Fill-finish assemblies and related methods
US20200261648A1 (en) 2017-11-06 2020-08-20 Amgen Inc. Drug delivery device with placement and flow sensing
IL319987A (en) 2017-11-10 2025-06-01 Amgen Inc Pistons for drug delivery devices
AU2018368338B2 (en) 2017-11-16 2024-07-25 Amgen Inc. Autoinjector with stall and end point detection
SG11202003004RA (en) 2017-11-16 2020-04-29 Amgen Inc Door latch mechanism for drug delivery device
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
CA3103681A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023451A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
EP3829692A1 (en) 2018-07-31 2021-06-09 Amgen Inc. Fluid path assembly for a drug delivery device
EP3856284A1 (en) 2018-09-24 2021-08-04 Amgen Inc. Interventional dosing systems and methods
MA53718A (en) 2018-09-28 2022-01-05 Amgen Inc MUSCLE WIRE ESCAPE ACTIVATOR SET FOR DRUG DELIVERY DEVICE
MX2021003492A (en) 2018-10-02 2021-06-18 Amgen Inc INJECTION SYSTEMS FOR THE ADMINISTRATION OF DRUGS WITH TRANSMISSION OF INTERNAL FORCE.
JP7547325B2 (en) 2018-10-05 2024-09-09 アムジエン・インコーポレーテツド Drug delivery device having a dosage indicator - Patents.com
AU2019359801B2 (en) 2018-10-15 2025-01-02 Amgen Inc. Platform assembly process for drug delivery device
SG11202103800RA (en) 2018-10-15 2021-05-28 Amgen Inc Drug delivery device having damping mechanism
ES3010833T3 (en) 2018-11-01 2025-04-04 Amgen Inc Drug delivery devices with partial drug delivery member retraction
TWI831847B (en) 2018-11-01 2024-02-11 美商安進公司 Drug delivery devices with partial needle retraction and methods for operating the same
MA54057A (en) 2018-11-01 2022-02-09 Amgen Inc DRUG DELIVERY ELEMENT PARTIAL RETRACTION DRUG DELIVERY DEVICES
AU2020263289B2 (en) 2019-04-24 2025-05-22 Amgen Inc. Syringe sterilization verification assemblies and methods
MX2022002149A (en) 2019-08-23 2022-03-17 Amgen Inc Drug delivery device with configurable needle shield engagement components and related methods.
US20230151071A1 (en) * 2020-04-09 2023-05-18 United States Government As Represented By The Department Of Veterans Affairs Compositions comprising recombinant epo and methods of use thereof
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
IL301396A (en) 2020-09-30 2023-05-01 Nobell Foods Inc Recombinant milk proteins and food compositions containing them
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
WO2022115396A1 (en) * 2020-11-25 2022-06-02 Jecho Laboratories, Inc. Il-7 fusion protein and related methods
MX2023013640A (en) 2021-05-21 2023-11-30 Amgen Inc Method of optimizing a filling recipe for a drug container.
KR20250099137A (en) 2022-11-02 2025-07-01 에프. 호프만-라 로슈 아게 Method for producing a glycoprotein composition
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0427189A1 (en) * 1989-11-07 1991-05-15 Snow Brand Milk Products Co., Ltd. Modified forms of human erythropoietin and DNA sequences encoding genes which can express them
WO1995033057A1 (en) * 1994-05-27 1995-12-07 Menarini Ricerche Sud S.P.A. Hybrid molecule of formula gm-csf-l-epo or epo-l-gm-csf for hematopoietic stimulation
WO1996019573A1 (en) * 1994-12-19 1996-06-27 Cangene Corporation Recombinant dna molecules and expression vectors for erythropoietin
WO1998004718A1 (en) * 1996-07-26 1998-02-05 Novartis Ag Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (en) 1983-12-13 1985-07-11 원본미기재 Method for preparing erythropoietin
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US4835260A (en) 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
PT88641B (en) 1987-10-02 1993-04-30 Genentech Inc METHOD FOR PREPARING A VARIETY OF ADHESION
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
US5061786A (en) 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
FR2650598B1 (en) 1989-08-03 1994-06-03 Rhone Poulenc Sante DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
AU646822B2 (en) 1989-10-13 1994-03-10 Kirin-Amgen Inc. Erythropoietin isoforms
JPH03201987A (en) 1989-12-29 1991-09-03 Tonen Corp Human serum albumin fragment
EP0606217B2 (en) * 1991-06-27 2008-12-03 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
CN1125401A (en) 1993-04-29 1996-06-26 艾博特公司 Erythropoietin analog compositions and methods
IL192290A0 (en) 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
US5959171A (en) * 1994-08-17 1999-09-28 Pharming B.V. Method for the production of biologically active polypeptides in a mammal's
US5547089A (en) 1994-09-19 1996-08-20 Westinghouse Air Brake Company Slackless drawbar assembly utilizing a ball and race assembly
JP3201987B2 (en) 1997-09-09 2001-08-27 株式会社オーレック Mowing equipment
US20050181482A1 (en) * 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
DE69933216T2 (en) * 1998-06-15 2007-09-20 GTC Biotherapeutics, Inc., Framingham ERYTHROPOIETIN ANALOG HUMAN SERUM ALBUMIN FUSION PROTEIN
EP1228214A2 (en) * 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
EP1274720A4 (en) * 2000-04-12 2004-08-18 Human Genome Sciences Inc ALBUMIN FUSED PROTEINS
PL362324A1 (en) * 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US7087719B2 (en) * 2002-11-19 2006-08-08 Gtc Biotherapeutics, Inc. Method for the crystallization of human serum albumin
US7550263B2 (en) * 2003-09-05 2009-06-23 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0427189A1 (en) * 1989-11-07 1991-05-15 Snow Brand Milk Products Co., Ltd. Modified forms of human erythropoietin and DNA sequences encoding genes which can express them
WO1995033057A1 (en) * 1994-05-27 1995-12-07 Menarini Ricerche Sud S.P.A. Hybrid molecule of formula gm-csf-l-epo or epo-l-gm-csf for hematopoietic stimulation
WO1996019573A1 (en) * 1994-12-19 1996-06-27 Cangene Corporation Recombinant dna molecules and expression vectors for erythropoietin
WO1998004718A1 (en) * 1996-07-26 1998-02-05 Novartis Ag Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DELORME E ET AL: "ROLE OF GLYCOSYLATION ON THE SECRETION AND BIOLOGICAL ACTIVITY OF ERYTHROPOIETIN", BIOCHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. EASTON, PA, vol. 31, pages 9871-9876, XP002053704, ISSN: 0006-2960 *

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041478B2 (en) 1992-01-31 2006-05-09 Aventis Behring L.L.C. G-CSF and albumin fusion protein
US7435410B2 (en) 1992-01-31 2008-10-14 Novozymes Biopharma Uk Limited Methods of treatment with interferson and albumin fusion protein
US7410779B2 (en) 1992-01-31 2008-08-12 Novozymes Biopharma Uk Limited Fusion polypeptides of human serum albumin and a therapeutically active polypeptide
US7094577B2 (en) 1992-01-31 2006-08-22 Aventis Behring L.L.C. Insulin and albumin fusion protein
US7081354B2 (en) 1992-01-31 2006-07-25 Aventis Behring L.L.C. Interleukin and albumin fusion protein
US6972322B2 (en) 1992-01-31 2005-12-06 Aventis Behring L.L.C. Interferon and albumin fusion protein
US6987006B2 (en) 1992-01-31 2006-01-17 Aventis Behring L.L.C. Erythropoietin and albumin fusion protein, nucleic acids, and methods thereof
US6989365B2 (en) 1992-01-31 2006-01-24 Aventis Behring L.L.C. Methods of treatment with erythropoietin and albumin fusion protein
US7056701B2 (en) 1992-01-31 2006-06-06 Aventis Behring L.L.C. Hormone and albumin fusion protein
US7550432B2 (en) 1995-12-30 2009-06-23 Novozymes Biopharma Uk Limited Recombinant fusion proteins to growth hormone and serum albumin
US7045318B2 (en) 1995-12-30 2006-05-16 Delta Biotechnology Limited Recombinant fusion proteins to growth hormone and serum albumin
US6838260B2 (en) 1997-12-08 2005-01-04 Emd Lexigen Research Center Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US7226998B2 (en) 1997-12-08 2007-06-05 Emd Lexigen Research Center Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US7576193B2 (en) 1997-12-08 2009-08-18 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7141651B2 (en) 1999-08-09 2006-11-28 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
US7582288B2 (en) 1999-08-09 2009-09-01 Merck Patent Gmbh Methods of targeting multiple cytokines
US7211253B1 (en) 1999-11-12 2007-05-01 Merck Patentgesellschaft Mit Beschrankter Haftung Erythropoietin forms with improved properties
US7091321B2 (en) 2000-02-11 2006-08-15 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US7507406B2 (en) 2000-02-11 2009-03-24 Emd Serono Research Center, Inc. Enhancing the circulating half-life of antibody-based fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7482013B2 (en) 2000-04-12 2009-01-27 Human Genome Sciences, Inc. Albumin fusion proteins
US6994857B2 (en) 2000-04-12 2006-02-07 Human Genome Sciences, Inc. Albumin fusion proteins
US7507414B2 (en) 2000-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US6905688B2 (en) 2000-04-12 2005-06-14 Human Genome Sciences, Inc. Albumin fusion proteins
US7517526B2 (en) 2000-06-29 2009-04-14 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US7148321B2 (en) 2001-03-07 2006-12-12 Emd Lexigen Research Center Corp. Expression technology for proteins containing a hybrid isotype antibody moiety
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7601814B2 (en) 2001-03-30 2009-10-13 Merck Patent Gmbh Reducing the immunogenicity of fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US6969517B2 (en) 2001-05-03 2005-11-29 Emd Lexigen Research Center Corp. Recombinant tumor specific antibody and use thereof
US7459538B2 (en) 2001-05-03 2008-12-02 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
US7186804B2 (en) 2001-12-04 2007-03-06 Emd Lexigen Research Center Corp. IL-2 fusion proteins with modulated selectivity
US7462350B2 (en) 2001-12-04 2008-12-09 Emd Serono Research Center, Inc. Cancer treatments including administering IL-2 fusion proteins with modulated selectivity
US9296809B2 (en) 2001-12-21 2016-03-29 Human Genome Sciences, Inc. Albumin fusion proteins
US7141547B2 (en) 2001-12-21 2006-11-28 Human Genome Sciences, Inc. Albumin fusion proteins comprising GLP-1 polypeptides
US7592010B2 (en) 2001-12-21 2009-09-22 Human Genome Sciences, Inc. Albumin fusion proteins
US8993517B2 (en) 2001-12-21 2015-03-31 Human Genome Sciences, Inc. Albumin fusion proteins
US9221896B2 (en) 2001-12-21 2015-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
US7238667B2 (en) 2001-12-21 2007-07-03 Human Genome Sciences, Inc. Albumin fusion proteins
US7169904B2 (en) 2002-12-17 2007-01-30 Emd Lexigen Research Center Corp. Immunocytokine sequences and uses thereof
US7521424B2 (en) 2003-01-22 2009-04-21 Human Genome Sciences, Inc. Albumin fusion proteins
US7465447B2 (en) 2003-12-31 2008-12-16 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
US9803011B2 (en) 2013-03-15 2017-10-31 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
US10239941B2 (en) 2013-03-15 2019-03-26 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof

Also Published As

Publication number Publication date
US6548653B1 (en) 2003-04-15
ES2273497T3 (en) 2007-05-01
DK1088084T3 (en) 2007-01-29
EP1088084B1 (en) 2006-09-13
US20020155998A1 (en) 2002-10-24
HK1036475A1 (en) 2002-01-04
DE69933216T2 (en) 2007-09-20
US7101971B2 (en) 2006-09-05
EP1088084A2 (en) 2001-04-04
ATE339507T1 (en) 2006-10-15
AU4566899A (en) 2000-01-05
JP2002518018A (en) 2002-06-25
AU775422B2 (en) 2004-07-29
US20040143857A1 (en) 2004-07-22
CA2330527A1 (en) 1999-12-23
DE69933216D1 (en) 2006-10-26
WO1999066054A2 (en) 1999-12-23
JP4087563B2 (en) 2008-05-21
US20050158832A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
DK1088084T3 (en) Erythropoietin analog-human serum albumin fusion protein
AU3562299A (en) Inhibin-hbc fusion protein
AU3827695A (en) Antigen-binding fusion proteins
AU2001264563A1 (en) Albumin fusion proteins
AU9482098A (en) Fusion protein systems
HUP0200414A2 (en) Interferon-betha fusion proteins and uses
AU2527397A (en) Fas ligand fusion proteins and their uses
AU7274898A (en) Recombinant antibody-enzyme fusion proteins
AU6058500A (en) Fusion protein and uses thereof
AU2002364586A1 (en) Albumin fusion proteins
AU2002364587A1 (en) Albumin fusion proteins
ZA9711239B (en) OB fusion protein compositions and methods.
WO1999002711A3 (en) Fusion proteins with an immunoglobulin hinge region linker
AU5065198A (en) Fusion proteins having increased half-lives
AU4572899A (en) Variant type ii tgf-beta receptor fusion proteins and methods
AU8182298A (en) Recombinant erythropoietin / immunoglobulin fusion proteins
AU1952497A (en) Novel antibody-cytokine fusion protein, and methods of making and using the same
AU2002332041A1 (en) Albumin fusion proteins
AU6059699A (en) Synthetic peptides, conjugation reagents and methods
AU5340399A (en) Proteases and associated proteins
AU6873596A (en) Allergen-xcd32 fusion proteins
AU9798398A (en) Gfp-annexin fusion proteins
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
AU9105698A (en) Rab proteins
AU5137698A (en) Novel dna, novel protein, and novel antibody

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 45668/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2330527

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999928656

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 554863

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999928656

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 45668/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999928656

Country of ref document: EP